Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Genscript BiotechGNNSF +8.44%73 Cash Ratio is 1.11 as of Jun. 2026, which is 63% below its 10-year median of 2.97. GuruFocus rates GNNSF with a GF Score™ of 73/100 and a GF Value™ of $2.12 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 1,328 Biotechnology companies, Genscript Biotech ranks worse than 71.69% on this metric.
Genscript Biotech has a Cash Ratio of 1.11. It generally indicates that the company is able to cover all short-term debt and still have cash remaining.
The historical rank and industry rank for Genscript Biotech's Cash Ratio or its related term are showing as below:
GNNSF'
s Cash Ratio Range Over the Past 10 Years
Min: 0.47 Med: 2.97 Max: 4.89
Current: 1.11
During the past 12 years, Genscript Biotech's highest Cash Ratio was 4.89. The lowest was 0.47. And the median was 2.97.
GNNSF's Cash Ratio is ranked worse than 71.69% of 1328
companies
in the Biotechnology industry
Industry Median: 3.03
vs GNNSF: 1.11
Genscript Biotech (OTCPK:GNNSF) Cash Ratio Explanation
The cash ratio is more conservative than other liquidity ratios, such as Quick Ratio and Current Ratio, because it only considers a company's most liquid resources. The numerator of cash ratio only considers Cash, Cash Equivalents and marketable securities. Other current assets, such as accounts receivable and inventories, are not included. The rationale is that these assets may require time to be transformed into cash, and the amount of money received is also uncertain.
The cash ratio shows a company’s ability to pay all current liabilities immediately without selling or liquidating other assets. Generally speaking, a higher cash ratio suggests the company has a stronger ability to cover its short-term debt. However, a high cash ratio could also indicate inefficient management: the company is inefficient in making full utilization of cash to invest protential profitable project. It may also suggest that the company is not confident about future profitability.
In general, the higher the cash ratio, the better the company's liquidity position.
Genscript Biotech Cash Ratio Related Terms
Genscript Biotech Cash Ratio Historical Data
* Premium members only.
The historical data trend for Genscript Biotech's Cash Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Biotechnology subindustry, Genscript Biotech's Cash Ratio, along with its competitors' market caps and Cash Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Genscript Biotech Cash Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Genscript Biotech's Cash Ratio distribution charts can be found below:
* The bar in red indicates where Genscript Biotech's Cash Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Genscript Biotech (GNNSF) has a Cash Ratio of 1.11 as of Jun. 2026. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Genscript Biotech and its competitors. This is 63% below median its historical median of 2.97. Over the past decade, Genscript Biotech's Cash Ratio has ranged from 0.47 to 4.89. According to the industry distribution chart, Genscript Biotech ranks #952 out of 1328 companies in the Biotechnology industry, placing it in the top 71.7%.
Is Genscript Biotech's Cash Ratio too high?
Genscript Biotech's current Cash Ratio of 1.11 is 63% below median its 10-year median of 2.97. Over the past 10 years, this metric has ranged from a low of 0.47 to a high of 4.89. The Biotechnology industry median Cash Ratio is 3.03. Genscript Biotech's value of 1.11 is 63.4% below this industry median. Based on the distribution chart, Genscript Biotech ranks #952 out of 1328 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Genscript Biotech has a GF Score™ of 73/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Genscript Biotech's Cash Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Genscript Biotech ranks #952 out of 1328 companies for Cash Ratio. This places Genscript Biotech in the lower half of its industry. The industry median Cash Ratio is 3.03. Genscript Biotech's value of 1.11 is 63.4% below this benchmark. Historically, Genscript Biotech's own Cash Ratio has ranged from 0.47 to 4.89 over the past decade. While the company's 10-year median is 2.97 vs. the industry median of 3.03, Genscript Biotech has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cash Ratio for a Biotechnology company?
The median Cash Ratio among Biotechnology companies is 3.03, based on 1,328 companies in the industry. Companies in the top quartile (top 25%) have a Cash Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cash Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Genscript Biotech's current Cash Ratio of 1.11 is 63.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cash Ratio mean?
A high Cash Ratio can signal that a stock is expensive relative to its fundamentals. Cashflow ratio is the ratio of Cash, Cash Equivalents, Marketable Securities to current liabilities. View historical data on Genscript Biotech and its competitors. For the Biotechnology industry, the median Cash Ratio is 3.03 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Genscript Biotech's current Cash Ratio is 1.11, which is 63% below median its own 10-year median of 2.97. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Genscript Biotech stock overvalued right now?
Based on GuruFocus' analysis, Genscript Biotech (GNNSF) is currently considered Significantly Overvalued. The stock's GF Value™ is $2.12, compared to a current price of $4.50 — trading 112.3% above its estimated fair value. The current Cash Ratio is 1.11, which is 63% below median its 10-year median of 2.97 and 63.4% below the Biotechnology industry median of 3.03. Genscript Biotech's overall GF Score™ is 73/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cash Ratio calculated?
Cash Ratio is calculated from a company's financial statements. For Genscript Biotech (GNNSF), the current Cash Ratio is 1.11 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Genscript Biotech (GNNSF) Overvalued in 2026?
Based on GuruFocus' analysis, Genscript Biotech stock appears to be overvalued.
The current stock price of $4.50 is trading 112.3% above its estimated GF Value™ of $2.12.
GuruFocus considers Genscript Biotech to be Significantly Overvalued.
Key valuation signals for GNNSF:
Cash Ratio: 1.11 (63% below median its 10-year median of 2.97)
GF Value™: $2.12 vs. price of $4.50 (112.3% above fair value)
Industry Position: 63.4% below the Biotechnology median (#952 of 1328)
No single metric tells the full story. See the GNNSF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
GenScript Biotech Corp is an investment holding company engaged in the manufacture and sale of life science research products and services, including life science services and products, biologics development services, and industrial synthetic biology products. Its segments include life science services and products, which generate maximum revenue and provide research services and products; biologics development services, which support the development of therapeutic antibodies and CGT products; industrial synthetic biology, which provides enzyme development and production using engineered microbial strains; and the operation unit, which provides shared services. It operates in Mainland China, which generates maximum revenue, U.S., Europe, and the Asia Pacific excluding Mainland China.
73GF Score
Get the complete analysis for GNNSF
Cash Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
GNNSF has been successfully added to your 
